Neoleukin Therapeutics Inc
Change company Symbol lookup
Select an option...
NLTX Neoleukin Therapeutics Inc
CTO CTO Realty Growth Inc
WHR Whirlpool Corp
OTIS Otis Worldwide Corp
GME GameStop Corp
ECF Ellsworth Growth and Income Fund Ltd
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.

Closing Price
$0.59
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
40,499

10-day average volume:
60,091
40,499

Under Armour shares rise after it tops estimates

7:15 am ET November 3, 2022 (MarketWatch)
Print

Under Armour Inc. shares rose 2% in premarket trades on Thursday after the athletic clothing maker topped analyst estimates for adjusted earnings and revenue. The Baltimore-based company said its second-quarter net income fell to $86.83 million, or 19 cents a share, from $113.44 million, or 24 cents a share, in the year-ago quarter. Adjusted net income totaled 20 cents a share. Second-quarter revenue rose to $1.57 billion from $1.55 billion. Wall Street analysts expected Under Armor to earn 16 cents a share on revenue of $1.55 billion, according to FactSet data. Looking ahead, the athletic clothing maker trimmed its fiscal 2023 revenue to increase at a low single-digit percentage rate, down from its earlier guidance of up 5% to 7%.

-Steve Gelsi

	

(END) Dow Jones Newswires

November 03, 2022 07:15 ET (11:15 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.